ArticleAmerican journal of translational research2022
Clinical efficacy and safety of flunarizine tablets combined with betahistine hydrochloride tablets in patients with vertebrobasilar insufficiency vertigo.
Article in American journal of translational research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
- Effects of flunarizine combined with ginkgo leaf extract and dipyridamole injection on hemorheology in elderly patients with vertigo.Pakistan journal of medical sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the clinical efficacy and safety of betahistine hydrochloride tablets in patients with vertebrobasilar insufficiency vertigo (VBIV).
methodsA total of 133 patients with vertigo caused by vertebrobasilar insufficiency treated in The First People's Hospital of Shangqiu City from March 2019 to August 2021 were selected and analyzed retrospectively. Among them, 63 patients treated with flunarizine tablets were seen as the control group (CG), and 70 with flunarizine tablets combined with betastine hydrochloride tablets were considered as the observation group (OG). The treatment efficacy and adverse reactions were compared, and the vertigo symptom score, quality of life and vertebrobasilar artery hemodynamics were observed before and after treatment.
resultsThe effective rate in the OG was higher than that of the CG (P<0.05), but there was no obvious difference in adverse reactions (P>0.05). Compared with the CG, the arterial hemodynamics and cerebral blood perfusion as well as SF-36 score were higher, while the scores of dizziness assessment rating scale (DARS) and dizziness handicap inventory (DHI) scale were lower in the OG (all P<0.05).
conclusionBetahistine hydrochloride can effectively improve arterial hemodynamics and cerebral blood flow perfusion in vertebrobasilar insufficiency patients and enhance the clinical efficacy with high safety profile, which is worthy of wide application.
Indexed as
Identifiers
36505311PMC9730052W4311281884What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.